Form 4: Travere Therapeutics Director Acquires Shares

Travere Therapeutics Director Timothy Coughlin acquired 4,000 shares of common stock through an automatic equity grant.

Summary

• Timothy Coughlin, a Director at Travere Therapeutics, Inc., acquired 4,000 shares of common stock on May 19, 2026.
• This acquisition was an automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, as part of the non-employee director compensation program.
• The equity award vests over a one-year period.
• Following this transaction, Coughlin beneficially owns 56,250 shares of common stock.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a routine equity grant to a director as part of a compensation plan, rather than a significant strategic event or financial performance indicator.

Positives

• Director Timothy Coughlin received an equity grant, indicating continued alignment with the company's performance.
• The acquisition of 4,000 shares of common stock demonstrates an investment in the company by a key insider.

Future Outlook

The filing does not contain forward-looking statements or guidance.

Industry Context

StockSavvy.ai notes that insider equity grants are a common practice in the biopharmaceutical industry, particularly for non-employee directors, to align their interests with shareholders and incentivize long-term company growth.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grant aligns director interests with shareholder value, potentially leading to better governance and strategic decisions.
• Employees: The grant reinforces the company's compensation structure for key personnel.
• Management: The grant is part of the established compensation framework for directors.

Next Steps

• The equity award vests over a one-year period.

Key Dates

Keywords

Travere Therapeutics, TVTX, Form 4, Insider Trading, Equity Grant, Director Compensation, Securities Exchange Act